MarketScreener

Lb Pharmaceuticals Inc Presents New Preclinical Data Supporting Lb-102?S Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs At 39Th ...

The poster features the design of the ongoing, potentially registrational Phase 2 ILLUMINATE-1 trial evaluating the efficacy and safety of once-daily LB-102 monotherapy in adults with bipolar ...
Business Wire

Newron to Present Three Posters on Its Clinical Program Evaluating Evenamide in the Treatment of Schizophrenia at the 36 th European College of Neuropsychopharmacology Congress

MILAN--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the ...
Business Wire

Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric ...
Yahoo Finance

LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
markets.financialcontent

Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. Karuna Therapeutics, Inc. (NASDAQ: KRTX), a ...